FDA Generic Drugs Advisory Committee
Agenda for Sept. 12-13 meeting includes a re-examination of the July 1992 Interim Guidance for Topical Corticosteroids: In Vivo Bioequivalence and In Vitro Release Methods," July 27 Federal Register notice states. The committee, with representation from FDA's Dermatologic Drugs Advisory Committee, will discuss pharmacodynamic (vasoconstrictor) measurement of bioequivalence on both days. On Sept. 13, the committee will consider other issues related to the documentation of equivalence according to the interim guidance. Discussion will be limited to dermatologic products and will not include ophthalmic or inhaled corticosteroid products." The meeting will be held in Conference Rooms G-J in FDA's Parklawn Building beginning at 8:30 a.m. both days
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth